Emyria has entered into a binding research study agreement with charity Reach Wellness to manage a pivotal observational study to evaluate the effectiveness of Emyria’s MDMA-assisted therapy (MDMA-AT) program, together with a support program managed by Reach Wellness, for first responders with PTSD.
Reach Wellness has embarked on a vital fundraising effort to cover all treatment and follow-up costs for an initial cohort of 50 suitably screened first responders who are struggling with PTSD and eligible for MDMA-AT.
Emyria CEO, Dr Michael Winlo, said:
“We are delighted to partner with Reach Wellness to help improve the treatment and support of Australia’s first responders who are impacted by mental health conditions like PTSD. We are committed to evaluating the impact of emerging approaches like MDMA-Assisted Therapy and the team at Reach shares our vision and is committed to backing it financially, with the support of its generous donors.”